5 days After Plunging -31.22% in 4 Weeks, Here’s Why the Trend Might Reverse for Lyell Immunopharma (LYEL) Zacks
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
X